Drugs / MB1707
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05465590 | Dec 2022 → Nov 2024 | breast cancer, non-small cell lung carcinoma, ovarian cancer, pancreatic neoplasm | Mainline Biosciences, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MB1707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05465590 ↗ |
| Action | Inhibit | “MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway.” NCT05465590 ↗ |
| Modality | Peptide | “MB1707 is a CXCR4 antagonist peptide-conjugated paclitaxel.” NCT05465590 ↗ |
| Target | CXCR4 | “MB1707 is a potent CXCR4 antagonist which inhibits tumor growth and metastasis by blocking the stromal cell derived factor 1 (SDF-1, a.k.a. CXCL12)/CXCR4 signaling pathway.” NCT05465590 ↗ |